Stanford Starts Incyte (INCY) at Buy
More News related to INCY
- Incyte to Present at the 20th Annual Piper Jaffray Health Care Conference
- Beacon Equity Issues Technical Trade Alerts on Market Movers: INCY, QLTI, LINTA, PDGI, FRPT, SVNT
- Incyte Reports Progress in Multiple Clinical Programs Announces Third Quarter Financial Results
- Incyte to Present at 2008 DB-Biotech Boston Confab
- Incyte (INCY) Announces Clinical Results from Phase IIa Trial on INCB18424 JAK Inhibitor
More News related to New Coverage
- Friedman Billings Starts Aircastle (AYR) at Underperform
- Friedman Billings Starts Netflix (NFLX) at Market Perform
- Credit Suisse Starts 3PAR (PAR) at Neutral
- Credit Suisse Starts Netezza (NZ) at Neutral
- FBR Starts Amazon.com (AMZN) at Market Perform
Stanford Group initiates coverage on Incyte (Nasdaq: INCY) with a Buy rating.
Incyte Corporation operates as a drug discovery and development company, which focuses on developing proprietary small molecule drugs to treat human immunodeficiency virus (HIV), diabetes, oncology, and inflammation diseases.
Related Categories
New CoverageStocks Mentioned
-0.41Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
